NVCT

$20.22+13.85%visit website

Nuvectis Pharma, Inc.

Market Cap

$695M

Live price × SEC shares (Oct 30, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

-0.19

56mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

5.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Research & development	5,086	4,106	4,684	27,370	41,246
Operating income	(7,617)	(6,260)	(7,197)	(31,049)	(52,123)
Net income	(7,314)	(6,050)	(7,020)	(30,070)	(50,454)
EPS (basic) ($)		(0.26)	(0.30)	(1.02)	(2.00)
EPS (diluted) ($)		(0.26)	(0.30)	(1.02)	(2.00)
Weighted avg. shares (basic)		23,414	23,476	29,467
Weighted avg. shares (diluted)		23,414	23,476	29,467

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 4, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 19 more quarters, back to Mar 2021, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 4, 2026 accepted 7:06 AM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

43%

W/W -8.1pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-06-30	2026-07-01	BENTSUR RON	Director & Chairman & CEO	Purchase	12.5K	$20.00	$250K	3.69M	View
2026-06-30	2026-07-01	Mosseri Marlio Charles	10% Owner	Purchase	50.0K	$18.32	$916K	3.19M	View